Observational studyBMC cancer2026
Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced nausea and vomiting (CINV) is a distressing adverse effect of chemotherapy that requires aggressive prevention. This study aimed to evaluate the antiemetic efficacy of a 4-day dexamethasone (DEX) regimen compared with the guideline-recommended 1-day DEX regimen against delayed CINV in patients receiving low-emetic-risk chemotherapy (LEC).
methodsPooled patient-level data from a multicenter, prospective, observational study, including 132 patients receiving LEC, divided into 1-day and 4-day DEX groups, were analyzed. An inverse probability of treatment weighting (IPTW) model was applied to balance patient characteristics. The primary endpoint was the incidence of delayed CINV, with secondary endpoints including symptom severity, food intake, and daily incidence patterns.
resultsAfter IPTW adjustment, the incidence of delayed nausea was significantly lower in the 4-day DEX group (3.19%) than in the 1-day group (22.78%, p = 0.001), with no significant difference in acute nausea between the groups (14.49% vs. 5.83%, p = 0.167). In a multivariate model, both female sex and the 1-day DEX regimen were independently associated with a higher risk of delayed CINV. The 4-day DEX group showed favorable trends in nausea incidence, severity, and food intake regardless of the presence of acute CINV.
conclusionsAlthough 1-day DEX remains the standard approach recommended by antiemetic guidelines, a 4-day DEX regimen shows promise as an alternative strategy for managing delayed nausea, especially in patients who experience acute CINV or have inadequate symptom control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.